Acquisition of BioNovion Holding, B.V. - Additional Information (Details) - USD ($)		1 Months Ended	3 Months Ended								12 Months Ended
	Oct. 30, 2015	Sep. 30, 2016	Dec. 31, 2016	Sep. 30, 2016	Jun. 30, 2016	Mar. 31, 2016	Dec. 31, 2015	Sep. 30, 2015	Jun. 30, 2015	Mar. 31, 2015	Dec. 31, 2016	Dec. 31, 2015	Dec. 31, 2014
Business Acquisition [Line Items]
Revenue			$ 3,878,000	$ 3,794,000	$ 38,979,000	$ 4,030,000	$ 34,376,000	$ 19,146,000	$ 9,883,000	$ 9,574,000	$ 50,681,000	$ 72,979,000	$ 13,389,000
Purchase price accounting measurement period adjustment to goodwill											$ (490,000)
Estimated life of intangible asset											20 years
Aduro Biotech Europe
Business Acquisition [Line Items]
Business combination, consideration transferred	$ 34,233,000
Issuance of common stock shares for acquisition of business	697,306
Revenue												288,000
Net loss												(595,000)
Fair value of Contingent Purchase Price	$ 3,775,000
Acquisition-related costs												572,000
Purchase price accounting measurement period adjustment to goodwill		$ 490,000
Business acquisition pro forma adjustments, acquisition related cost												2,300,000
Business acquisition pro forma adjustments, stock based compensation expense												2,100,000	5,300,000
Business acquisitions pro forma adjustments, amortization of intangible assets												$ 500,000	$ 600,000
Aduro Biotech Europe | License and Research Agreement
Business Acquisition [Line Items]
Estimated life of intangible asset	20 years
Intangible assets, amortization method											straight line basis